核苷酸酶CD73在恶性肿瘤中作用和调控机制的研究进展

doi:10.3969/j.issn.1004-616x.2020.05.013

癌变·畸变·突变 ›› 2020, Vol. 32 ›› Issue (5): 398-401.doi: 10.3969/j.issn.1004-616x.2020.05.013

核苷酸酶CD73在恶性肿瘤中作用和调控机制的研究进展

戚玉竹, 刘静, 张国君

汕头大学医学院长江学者实验室, 广东省乳腺癌诊治研究重点实验室, 广东汕头 515041

收稿日期:2019-05-30 修回日期:2020-07-27 出版日期:2020-10-01 发布日期:2020-10-12
通讯作者: 刘静,E-mail:jliu12@stu.edu.cn;张国君,E-mail:guoj_zhang@yahoo.com E-mail:jliu12@stu.edu.cn;guoj_zhang@yahoo.com
作者简介:戚玉竹,E-mail:353869745@qq.com。
基金资助:
国家自然科学基金（81501539，81320108015）；广东省自然科学基金（2016A030312008）。

Received:2019-05-30 Revised:2020-07-27 Online:2020-10-01 Published:2020-10-12

摘要/Abstract

摘要： 核苷酸酶CD73可酶解产生腺苷，参与腺苷通路，在多种恶性肿瘤发展进程中发挥重要作用。研究发现，CD73的高表达与多种类型肿瘤的发展进程、转移和不良生存预后密切相关。目前靶向CD73的治疗在多个动物实验中已经取得了显著疗效，为治疗恶性肿瘤提供了新的思路。本文旨在阐述CD73在肿瘤生长、转移等过程中的作用及分子机制，介绍抗CD73研究的新进展，为恶性肿瘤患者的个体化治疗提供新的潜在治疗方案。

关键词: CD73, 肿瘤, 增殖, 转移, 治疗

中图分类号:

R730.53

戚玉竹, 刘静, 张国君. 核苷酸酶CD73在恶性肿瘤中作用和调控机制的研究进展[J]. 癌变·畸变·突变, 2020, 32(5): 398-401.

参考文献

[1] GHALAMFARSA G, KAZEMI M H, RAOOFI MOHSENI S, et al. CD73 as a potential opportunity for cancer immunotherapy[J]. Expert Opin Ther Targets, 2019, 23(2):127-142.
[2] ZIMMERMANN H. 5'-Nucleotidase:molecular structure and functional aspects[J]. Biochem J, 1992, 285(Sup 2):345-365.
[3] ALLARD D, ALLARD B, GAUDREAU P O, et al. CD73-adenosine:a next-generation target in immuno-oncology[J]. Immunotherapy, 2016, 8(2):145-163.
[4] RESTA R, YAMASHITA Y, THOMPSON L F. Ecto-enzyme and signaling functions of lymphocyte CD73[J]. Immunol Rev, 1998, 161:95-109.
[5] STAGG J, SMYTH M J. Extracellular adenosine triphosphate and adenosine in cancer[J]. Oncogene, 2010, 29(39):5346-5358.
[6] TOCZEK M, PIERZYNOWSKA K, KUTRYB-ZAJAC B, et al. Characterization of adenine nucleotide metabolism in the cellular model of Huntington's disease[J]. Nucleosides Nucleotides Nucleic Acids, 2018, 37(11):630-638.
[7] ZHI X, WANG Y, ZHOU X, et al. RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells[J]. Cancer Sci, 2010, 101(12):2561-2569.
[8] SAMANTA D, PARK Y, NI X H, et al. Chemotherapy induces enrichment of CD47⁺/CD73⁺/PDL1⁺ immune evasive triple-negative breast cancer cells[J]. Proc Natl Acad Sci USA, 2018, 115(6):E1239-E1248.
[9] ALLARD D, ALLARD B, GAUDREAU P O, et al. CD73-adenosine:a next-generation target in immuno-oncology[J]. Immunotherapy, 2016, 8(2):145-163.
[10] WANG L, TANG S, WANG Y, et al. Ecto-5'-nucleotidase (CD73) promotes tumor angiogenesis[J]. Clin Exp Metastasis, 2013, 30(5):671-680.
[11] LEY K. Plugging the leaks[J]. Nat Med, 2001, 7(10):1105-1106.
[12] COMERFORD K M, LAWRENCE D W, SYNNESTVEDT K, et al. Role of vasodilator-stimulated phosphoprotein in protein kinase A-induced changes in endothelial junctional permeability[J]. FASEB J, 2002, 16(6):583-585.
[13] TURCOTTE M, ALLARD D, MITTAL D, et al. CD73 promotes resistance to HER2/ErbB2 antibody therapy[J]. Cancer Res, 2017, 77(20):5652-5663.
[14] PENG D, HU Z, WEI X, et al. NT5E inhibition suppresses the growth of sunitinib-resistant cells and EMT course and AKT/GSK-3β signaling pathway in renal cell cancer[J]. IUBMB Life, 2019, 71(1):113-124.
[15] NEVEDOMSKAYA E, PERRYMAN R, SOLANKI S, et al. A systems oncology approach identifies NT5E as a key metabolic regulator in tumor cells and modulator of platinum sensitivity[J]. J Proteome Res, 2016, 15(1):280-290.
[16] AIRAS L, HELLMAN J, SALMI M, et al. CD73 is involved in lymphocyte binding to the endothelium:characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73[J]. J Exp Med, 1995, 182(5):1603-1608.
[17] SADEJ R, SPYCHALA J, SKLADANOWSKI A C. Expression of ecto-5'-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma[J]. Melanoma Res, 2006, 16(3):213-222.
[18] ZHI X, WANG Y, YU J, et al. Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer[J]. IUBMB Life, 2012, 64(11):911-920.
[19] BUSSOLATI B, LAURITANO C, MOGGIO A, et al. Renal CD133+/CD73+ progenitors produce erythropoietin under hypoxia and prolyl hydroxylase inhibition[J]. J Am Soc Nephrol, 2013, 24(8):1234-1241.
[20] NIEMELÄ J, HENTTINEN T, YEGUTKIN G G, et al. IFN-alpha induced adenosine production on the endothelium:a mechanism mediated by CD73(ecto-5'-nucleotidase) up-regulation[J]. J Immunol, 2004, 172(3):1646-1653.
[21] YAMASHITA Y, HOOKER S W, JIANG H, et al. CD73 expression and Fyn-dependent signaling on murine lymphocytes[J]. Eur J Immunol, 1998, 28(10):2981-2990.
[22] FAUSTHER M, SHEUNG N, SAIMAN Y, et al. Activated hepatic stellate cells upregulate transcription of ecto-5'-nucleotidase/CD73 via specific SP1 and SMAD promoter elements[J]. Am J Physiol Gastrointest Liver Physiol, 2012, 303(8):G904-G914.
[23] MAZUMDER B, SESHADRI V, FOX P L. Translational control by the 3'-UTR:the ends specify the means[J]. Trends Biochem Sci, 2003, 28(2):91-98.
[24] WANG N, XIANG X H, CHEN K, et al. Targeting of NT5E by miR-30b and miR-340 attenuates proliferation, invasion and migration of gallbladder carcinoma[J]. Biochimie, 2018, 146:56-67.
[25] BONNIN N, ARMANDY E, CARRAS J, et al. MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma[J]. Oncotarget, 2016, 7(28):44023-44038.
[26] SCIARAFFIA E, RICCOMI A, LINDSTEDT R, et al. Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors[J]. J Leukoc Biol, 2014, 96(1):113-122.
[27] YANG X, PEI S, WANG H, et al. Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73[J]. BMC Cancer, 2017, 17(1):255.
[28] TERP M G, OLESEN K A, ARNSPANG E C, et al. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells[J]. J Immunol, 2013, 191(8):4165-4173.
[29] STAGG J, DIVISEKERA U, MCLAUGHLIN N, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis[J]. Proc Natl Acad Sci USA, 2010, 107(4):1547-1552.
[30] ANTONIOLI L, YEGUTKIN G G, PACHER P, et al. Anti-CD73 in cancer immunotherapy:awakening new opportunities[J]. Trends Cancer, 2016, 2(2):95-109.

核苷酸酶CD73在恶性肿瘤中作用和调控机制的研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵岩, 孙震晓. 二甲双胍抑制人MDA-MB-231细胞增殖及迁移的体外实验研究[J]. 癌变·畸变·突变, 2022, 34(1): 35-39.
[2]	祝欣萍, 贾迪, 林少辉, 刘晨, 李婧铱, 赵炜明. 新型多金属氧酸盐药物{BiW₈O₃₀}对肝癌SK-HEP-1细胞的抑制作用[J]. 癌变·畸变·突变, 2022, 34(1): 47-52,66.
[3]	问天娇, 李思颖, 郑颖, 崔京霞. 脂质体技术在铂类药物抗肿瘤研究中的应用[J]. 癌变·畸变·突变, 2022, 34(1): 72-74.
[4]	郭照萌, 张华, 张鹏. Orai1对鼻咽癌细胞侵袭和上皮-间充质转化的影响及其机制[J]. 癌变·畸变·突变, 2021, 33(6): 420-425.
[5]	刘宁, 梁兰兰, 李淑芳, 沈祥春, 梁冰. 氧化苦参碱对小鼠肉瘤和肝癌的体内外抗肿瘤作用[J]. 癌变·畸变·突变, 2021, 33(6): 426-429,434.
[6]	王晓舟, 李洪石, 于溪, 魏宁, 王梓瑛, 赫丽杰. 青藤碱对HPV阳性宫颈癌SiHa细胞增殖和侵袭的影响[J]. 癌变·畸变·突变, 2021, 33(6): 442-445.
[7]	王蕊, 王珩, 吴娟, 纪晓坤, 郭晓, 马阳, 杜芸. 全自动DNA图像分析系统在胰腺恶性肿瘤诊断中的价值[J]. 癌变·畸变·突变, 2021, 33(6): 451-454.
[8]	张宗敏. 甲状腺微小癌是否需要手术[J]. 癌变·畸变·突变, 2021, 33(5): 325-326.
[9]	孙惠昕, 张茂祥, 王婉莹, 贾海晗, 宋冰冰. 2013—2017年黑龙江省肿瘤登记地区前列腺癌发病死亡情况及趋势分析[J]. 癌变·畸变·突变, 2021, 33(5): 345-348.
[10]	马亚南, 吴楠, 金焰. 肿瘤微环境与卵巢癌化疗耐药机制的研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 393-395,400.
[11]	王琛瑶, 梁百慧, 吴锦源, 唐梓涵, 许小文, 尹梓健, 丁雅琼, 方雄钊, 李栢芝, 文姝佚, 程转, 詹涵, 张粤烽, 王泫哲, 何仕龙, 张可洵, 刘雅骐, 周飞, 熊兴东, 白春英, 许丽艳, 李恩民. RAC1对恶性肿瘤的调控作用及其分子机制研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 401-404.
[12]	黄晓华, 牛永东, 石刚刚. 核受体FXR激活对宫颈癌CaSki细胞增殖的抑制效应及其作用机制[J]. 癌变·畸变·突变, 2021, 33(4): 302-306.
[13]	程书钧. 衰老和恶性肿瘤──防治的思考[J]. 癌变·畸变·突变, 2021, 33(3): 161-162.
[14]	郑珺文, 常晨, 郝佳洁, 蔡岩, 王明荣, 张钰. NEDD4在食管鳞癌中的表达及作用研究[J]. 癌变·畸变·突变, 2021, 33(3): 203-207,224.
[15]	罗娇, 张坤驰, 周莉. 三阴性乳腺癌细胞系MDA-MB-231与其脑转移细胞系中microRNA差异表达分析[J]. 癌变·畸变·突变, 2021, 33(3): 218-224.